Sandoz, a subsidiary division of Novartis, has launched its infliximab biosimilar, Zessly, in Germany. The launch brings the number of infliximab biosimilars available in Germany to 3.
Sandoz, a subsidiary division of Novartis, recently launched its infliximab biosimilar, Zessly, in Germany. The launch brings the number of infliximab biosimilars available in Germany to 3.
In May 2018, the European Commission authorized the biosimilar for sale in the European Union (EU). Germany will be the first European market where the drug will be available for all indications of the reference product: rheumatoid arthritis (RA), adult Crohn disease, pediatric Crohn disease, adult ulcerative colitis, pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
The approval was based on a review of the data that demonstrated the infliximab biosimilar was equivalent to the reference product in terms of both safety and efficacy. The data included a phase 3 confirmatory study in RA that met its primary endpoint of achieving the American College of Rheumatology’s criteria for a 20% improvement (ACR20) response at week 14.
Reference infliximab, sold as Remicade and developed by Johnson & Johnson (J&J), earned an estimated $6.3 billion globally in 2017. However, increased competition from biosimilars is starting to eat away at its market share. During an investor call earlier this year that discussed fourth quarter sales from 2017, it was announced that Remicade sales fell by 9.7% worldwide.
In the United States, Remicade faces biosimilar competition from 2 products: Celltrion and Pfizer’s Inflectra, and Samsung Bioepis and Merck’s Renflexis. In the European Unoin, J&J’s reference infliximab fights for market share from the same products, though Renflexis is marketed under the brand name Flixabi, and Inflectra is marketed under 2 names: Inflectra and Remsima.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.